AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06155968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: the PCA pump will be connected in a separate cannula. The pump contains 0.5 mg nalbuphine/ ml. the basal rate is 5ml/h and lock out time is 10 min
Study NCT05780203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One session exposure treatment
Description: One session exposure treatment during which patients will be confronted with a height-related situation.
Study NCT05780203 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: One session exposure treatment
Description: One session exposure treatment during which patients will be confronted with a height-related situation.
Study NCT05780203 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Cognitive Bias Modification training
Description: Sham Cognitive Bias Modification training procedure matched in format to active training but adapted to not target height-related, interpretational processing biases.
Study NCT05780203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Cognitive Bias Modification training
Description: Active Cognitive Bias Modification training targeting height-related, interpretational processing biases.
Study NCT06299696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNZ/TEZ/D-IVA
Description: FDC granules for oral administration
Study NCT06031701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-psychosocial teleassistance program
Description: The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration. The intervention is aimed at strengthening aspects of social cognition, self-esteem, social skills and aims at a reduction of symptomatology and a general improvement of psychological well-being.
Study NCT05997043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral anti-Parkinson drugs and injection of botulinum toxin
Description: The experimental group was treated with oral anti-Parkinson drugs and injection of botulinum toxin
Study NCT05997043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral anti-Parkinson's drugs
Description: The control group only took oral anti-Parkinson's drugs.
Study NCT06016179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Each patient will receive four incremental weekly intra-cavitary doses of tocilizumab starting at 0.5μg/mL and increasing to 1.6μg/mL, 5μg/mL and 50μg/mL once a week over four weeks.
Study NCT04881396 — intervention group
Intervention type: BIOLOGICAL
Intervention: Evaluation of the immunogenicity of the vaccine in haemodialysis patients
Description: The immunogenicity of the vaccine will be evaluated at the peak of vaccine response (Day 7 - Day 14 after the second dose) and 6 and 12 months post vaccination, by the evaluation of humoral IgG anti-spike protein response (seroconversion rate, absolute antibody titers, affinity of antibody) and cellular anti SARS-Cov2 response (number, activation capacity, production of interferon gamma of CD4 and CD8 anti sars cov2 specific T cells)
Study NCT04520685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral cannabidiol 100mg/mL
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
Study NCT04520685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: In Arm 1, patients will begin CBD in period 1 and receive placebo in period 2. In Arm 2, patients will begin placebo in period 1 and receive CBD in period 2. In Arm 3, patients will receive CBD for the entire 27 week study duration without washout. Each study period is 12 weeks and dose will be titrated up for 1 week at the beginning of a treatment period and titrated down for 1 week at the end of a treatment period, with a two week placebo washout between periods for Arms 1 and 2. The titration dose will be 5mg/kg/day and the treatment dose will be 10mg/kg/day.
Study NCT06576453 — intervention group
Intervention type: BEHAVIORAL
Intervention: quiz of knowledge
Description: Parents must complete the quiz of knowledge after the first and the last session of the Pepps program.
Study NCT06576453 — intervention group
Intervention type: BEHAVIORAL
Intervention: semi-structured interviews (qualitative)
Description: In the month following the last session of the program, the semi-structured interviews (qualitative) will be carried out with parents who have followed either all or part of the sessions of the band.
Study NCT06576349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate And Loving Mindset towards Heart Health Risk (CALM Hearts) Intervention
Description: Self-compassion and health behaviour change intervention for women at risk for cardiovascular disease
Study NCT05393037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V116
Description: Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Study NCT05393037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline in each 0.5 mL sterile solution
Study NCT05393037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV15
Description: Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
Study NCT05393037 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPSV23
Description: Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Study NCT05393037 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV15 - Part B
Description: Pneumococcal 15-valent conjugate vaccine with 2 μg of each of the following PnPs antigen: 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F; and 4 μg of PnPs antigen 6B in each 0.5 mL sterile suspension
Study NCT06535334 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy
Description: Intravenous chemotherapy versus intraperitoneal chemotherapy in recurrent ovarian cancer
Study NCT05679947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization protocol
Description: The mobilization protocol includes six levels. Protocol levels are applied from the day the patient is operated and ends on the day of discharge. The researcher explains the protocol levels to the patient before surgery.The patient is mobilized within the first 24 hours after surgery. Implement mobilization protocol three times during the day and more as tolerated. Mobilization protocol:Level 1: Repositioning should occur every two hours. Level 2: Range of motion (PROM) should occur at least three times a day. Level 3: The head of bed (HOB) >30 degrees. Duration goal: 5-15 minutes. HOB 65≥ degrees with patient sit in the bed. Duration goal: 5-15 minutes. Progress to level 4. Level 4: HOB 65≥ degrees with legs in dependent position (recliner chair). Duration goal: 5-15 minutes. Progress to level 5. Level 5: Stand/pivot/step to chair. Sitting in chair. Duration goal: 5-15 minutes. Progress to level 6. Level 6: Patient is able to ambulate at least three times a day.
Study NCT04961385 — intervention group
Intervention type: BIOLOGICAL
Intervention: Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine
Description: Blood samples were taken from the vaccinated participants for antibody testing against SARS-CoV-2
Study NCT04932369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion Regulation training based on DBT
Description: trained about emotion regulation and problem solving during eight 90-min group sessions
Study NCT05028790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision contact lens
Description: Participants will wear a single vision soft contact lens during the study visit
Study NCT05028790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal contact lens
Description: Participants will wear a multifocal soft contact lens during the study visit
Study NCT03224689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEEK-Optima Femoral Component
Description: TKA Surgery
Study NCT05082259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX660
Description: ASTX660 will be supplied as capsules. Each hydroxylpropyl methylcellulose (HPMC) capsule contains either 30 mg or 90 mg of ASTX600 free-base equivalents, suitable for oral administration. Bottles are labelled with the capsule strength (ie, 30 mg or 90 mg) and are further distinguished by different-colored labels. Each bottle contains 14 capsules and an oxygen-absorber (not to be consumed).
Study NCT05082259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab Solution for Infusion 100 mg/vial is a liquid drug product supplied as a clear to opalescent solution, essentially free of visible particles, in Type I glass vials and manufactured using the fully formulated drug substance with L-histidine as buffering agent, polysorbate 80 as surfactant, and sucrose as stabilizer/tonicity modifier.~Pembrolizumab Solution for Infusion can be further diluted with normal saline or 5% dextrose in the concentration range of 1 to 10 mg/mL in IV containers made of polyvinyl chloride (PVC) or non-PVC material.
Study NCT04726696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROLE-AP programme
Description: The intervention group will be split in two groups of 7-8 primary care nurses each. These two groups will receive the ROLE-AP program over a three weeks period. Each workshop will be divided into two sessions of 90-120min. The first workshop focuses on the clarification of health promotion concepts and the discussion of the state of nursing practice in health promotion. Participants will discuss the misalignments between this description of nursing practice and the ideal one portrayed by the Ottawa Charter. The second workshop will allow the presentation of the objectives of the health care organization, showing its alignment with the Ottawa Charter areas of action. In addition, it will present a standardized instrument that reflects expectations about nurses' activities in health promotion that will serve for discussing and realigning participants' expectations on nurses' role in health promotion. The third workshop will continue with the discussion of nurses' expected activities.
Study NCT04988555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-5336
Description: DSP-5336 orally
Study NCT06048861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KForce Sens
Description: The device was attached to the middle of the wrist joint with the help of Velcro for all movements. Starting position of the extremity was determined and this position was introduced to the device as the reference position. Then, the participant was asked to perform the movement.
Study NCT06048861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline Electrıgoniometer
Description: The pivot point of the goniometer was placed next to the ulnar styloid for 30° and 60° wrist flexion and extension, and also it was placed in the middle carpometacarpal joint for radial and ulnar deviation. A passive movement was made to the extremity in a predetermined amount and direction. The participant was asked to remember this position. Then, the participant was asked to return the extremity to this position when their eyes were closed.
Study NCT06485050 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Application of red laser-photodynamic therapy using Rapid Podia Laser diode® (MEDENCY). The following protocol will be followed: 1) mechanical debridement of the nail, 2) disinfection of the nail with alcohol, 3) application of topical photosensitiser (Toluidine blue gel) for 5 minutes with the area covered, 5) application of 635 nm diode laser for 10 minutes.~Daily application of ciclopirox 8% with ethyl acetate, ethanol (96%), ketosteryl alcohol, hydroxypropyl chitosan and purified water.
Study NCT06174103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiVACOR TAH System
Description: The BiVACOR pump is an implantable rotary biventricular blood pump that uses magnetic levitation technology for increased durability to replace both ventricles of a failing heart. The device is intended to replace the diseased heart in patients suffering from heart failure to bridge the time to heart transplant.
Study NCT05002257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Patients included in the intervention arm with music therapy will choose among 3 possible music: music from elsewhere, classical music, today's music. These 3 music thearpy will have an identical duration of 20 minutes.
Study NCT05002257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No music therapy
Description: Usual care
Study NCT04952805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD0004J08
Description: MAD0004J08 is a human monoclonal Antibody (mAb), 2.5 mL 2R vial available in two dose: 100 mg and 400 mg. The pharmaceutical form is solution for intramuscular injection.
Study NCT04952805 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to MAD0004J08, 2.5 mL 2R vial. The pharmaceutical form is solution for intramuscular injection.
Study NCT04734210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.02% Betamethasone Sodium Phosphate
Description: topical corticosteroid solution
Study NCT04734210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.04% Betamethasone Sodium Phosphate
Description: topical corticosteroid solution
Study NCT04734210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical vehicle solution
Study NCT06634576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smooth pursuit neck torsion test
Description: Used custom-made system to stimulate the procedure of smooth pursuit neck torsion test in the current study, the multiple axis motion platform can adjust the neck postures to three different neck motion planes, seven different neck postures.
Study NCT06634485 — intervention group
Intervention type: DEVICE
Intervention: ultrasound, spirometry
Description: Ultrasound assessment of~1. diaphragmatic excursion:-the probe will be angled medially ,cranially , and dorsally so that the ultrasound beam reaches the posterior third of the diaphragm, in B-mode.Then, then M-mode exploration line will be placed perpendicular to the diaphragmatic dome to obtain maximum excursion .~2. (Tdi) will be measured using a high-frequency linear probe (10 MHz) placed on (ZA).The probe will be angled perpendicular to the lateral chest wall and placed between the midaxillary and anterior axillary lines at the eighth or ninth intercostal space.~3. Quadricep\|rectus femoris muscle assessment will be done by placing the transducer perpendicular to the long axis of the thigh.~   * Spirometry:-will be performed thrice by experienced technicians at our pulmonary function laboratory. Patients will be asked to take a maximal inspiration and then to forcefully expel air for as long and as quickly as possible.
Study NCT06634810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Management Support
Description: The intervention will be delivered by CHWs in person and supplemented with telephone or video encounters over 6 months. The intervention comprises six core elements: engagement, intake, self-management assessment, barrier screening, actions to address identified barriers, and follow-up/maintenance support.
Study NCT06634810 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: COPD Education
Description: The attention control is where CHWs will provide COPD education using the COPD 1-2-3 booklet. The attention control will consist of 6 CHW visits (approximately 1 per month) with the patient and care giver in their home or via video conference, per patient preference.
Study NCT06442462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPG302
Description: small synthetic molecule
Study NCT06442462 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06385938 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound with quantitative vibro-acoustic assessment
Description: Imaging with non-invasive bone assessment based on wide range of frequencies and free from soft tissue artifact of the wrists and the knees
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06029270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT06029270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT06029270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06029270 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT06029270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06029270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06029270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Given IV
Study NCT06003868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy
Description: Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
Study NCT06003868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional physiotherapy
Description: Stretching for patients with spasticity exercises walking exercises for balance and gait disorders muscle strengthening exercises relaxation exercises
Study NCT06003868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hippotherapy-assisted physiotherapy
Description: The patients will be placed on the simulator and the starting position will be taught. your simulator before the application and in order to maintain the starting position throughout their movements.~they will be warned during the applications.. Hippotherapy simulator is almost like walking.~pattern and will be run in the 1st stage of the 3-stage speed level.
Study NCT05495100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone liposome、Chidamide、Azacitidine
Description: Mitoxantrone liposome 20mg/m2, d1; Chidamide 20mg, biw; Azacitidine 100mg, d1\~7; Every 4 weeks is a cycle, with a maximum of 4 cycles of treatment.
Study NCT05565833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHUTi OASIS
Description: Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6-9 weeks in a fully automated, interactive, tailored web-based program
Study NCT05565833 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patient Education
Description: An educational website containing information on insomnia
Study NCT06363344 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires : PHQ-9 (Kroenke, 2001), the PSC (Sheldrick, 2012), the ASQ-SE (Squires, 2015), the PedsQL (Varni, 1999)
Description: An advanced practice nurse who is a member of the PICU team monitors patients by questionnaires at 1 and 3 months. Depending on the anomalies detected, whether at the somatic, psychological, emotional or social level, the nurse refers to competent specialists and collaborators and continues monitoring of the family as needed.
Study NCT05107908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Implicit Priming
Description: Approximately 10-minute behavioral intervention
Study NCT05107908 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Implicit Priming
Description: Approximately 10-minute behavioral intervention
Study NCT05107908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Exposure Task
Description: Approximately 10-30 minute behavioral intervention
Study NCT06024174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986466
Description: Specified dose on specified days
Study NCT06024174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Specified dose on specified days